Log in to your Inderes Free account to see all free content on this page.

Circio Holding

Less than 1K followers

CRNA

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

Circio Holding is a pharmaceutical company. The company's specialist expertise is found in targeted immunotherapy used in the treatment of cancer patients. The company's operations consist of research and development and the medicines are sold under separate brands. Several partnerships in the market have been entered into to strengthen cooperation in the development of new immunotherapy. The company was founded in 2010 and is headquartered in Lysaker.

Market cap

-

Turnover

-

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

15.4.

2026

Annual report '25

8.5.

2026

General meeting '26

31.8.

2026

Interim report Q2'26

All

Press releases

ShowingAll content types

Regulatory press release2/26/2026, 6:00 AM

Circio presents groundbreaking in vivo data showing up to 50-fold enhanced circVec-AAV gene expression in eye

Regulatory press release2/19/2026, 6:00 AM

Circio invites to R&D and corporate update webcast on 26 February 2026

Regulatory press release2/17/2026, 9:33 AM

Circio Holding ASA: Registration of share capital increase following directed issue of NOK 3.6 million

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release2/16/2026, 6:00 AM

CIRCIO HOLDING ASA: INFORMATION ABOUT WARRANTS AND COMMENCEMENT OF TRADING

Regulatory press release2/14/2026, 8:57 AM

Circio announces allocation of stock options to key employees

Regulatory press release2/12/2026, 10:12 PM

CRNA: Financial calendar

Regulatory press release2/12/2026, 11:19 AM

Circio Holding ASA: Registration of share capital increase following rights issue and private placement

Regulatory press release2/6/2026, 10:48 AM

Circio Holding ASA completes directed issue of NOK 3.6 million

Regulatory press release1/30/2026, 6:44 PM

Circio Holding ASA – Mandatory notification of trade by primary insiders and close associates related to the rights issue and private placement

Regulatory press release1/30/2026, 1:11 PM

Circio Holding ASA – Final results of the oversubscribed rights issue

Regulatory press release1/29/2026, 8:43 PM

Circio Holding ASA announces substantially oversubscribed preliminary result of the rights issue

Regulatory press release1/29/2026, 8:32 AM

Circio Holding ASA – Exercise of subscription rights in the rights issue by primary insiders

Regulatory press release1/29/2026, 6:00 AM

Circio Holding ASA – Subscription period for the rights issue expires today

Regulatory press release1/28/2026, 12:37 PM

Circio Holding ASA – Exercise of subscription rights in the rights issue by primary insiders

Regulatory press release1/23/2026, 6:00 AM

Circio Holding ASA – Last day of trading in subscription rights in the rights issue

Press release1/22/2026, 9:50 AM

Analyst Group publishes initiation report on Circio

Regulatory press release1/21/2026, 2:12 PM

Circio Holding ASA – Exercise of subscription rights in the rights issue by primary insiders

Regulatory press release1/16/2026, 1:06 PM

Circio Holding ASA – Exercise of subscription rights in the rights issue by primary insiders

Regulatory press release1/15/2026, 2:12 PM

Circio Holding ASA – Receipt of subscription rights in the rights issue by primary insiders and their close associates

Regulatory press release1/15/2026, 6:00 AM

Circio Holding ASA – Commencement of the subscription period for the rights issue

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.